VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. de Souza on Next Steps for Immunotherapy in Head and Neck Cancer

Jonas de Souza, MD
Published: Monday, Dec 19, 2016



Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

Potential next steps could include head-to-head comparisons of immunotherapy with the standard EXTREME regimen, which includes cetuximab (Erbitux) and platinum-based chemotherapy with 5-fluorouracil (5-FU). According to de Souza, future research should examine whether immunotherapy is active and efficacious in the first-line setting for metastatic patients.

A big remaining question, he says, concerns the treatment of HPV-positive patients with head and neck cancer, who may require less therapy than others. He questions whether these patients should be treated the same as other individuals, or if they should, perhaps, receive less radiation therapy or chemotherapy. Further research is warranted in this space, says de Souza.


Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

Potential next steps could include head-to-head comparisons of immunotherapy with the standard EXTREME regimen, which includes cetuximab (Erbitux) and platinum-based chemotherapy with 5-fluorouracil (5-FU). According to de Souza, future research should examine whether immunotherapy is active and efficacious in the first-line setting for metastatic patients.

A big remaining question, he says, concerns the treatment of HPV-positive patients with head and neck cancer, who may require less therapy than others. He questions whether these patients should be treated the same as other individuals, or if they should, perhaps, receive less radiation therapy or chemotherapy. Further research is warranted in this space, says de Souza.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x